Pfizer and Astellas gain positive trial results for prostate cancer treatment

Pfizer and Astellas have announced results from the Phase III ARCHES trial in men with metastatic hormone-sensitive prostate cancer (HSPC), showing that Enzalutamide had significantly improved radiographic progression-free survival, paving the way for an application to expand the drug’s use. The results, which are for the drug in combination with androgen deprivation therapy, show a

Continue Reading

Celgene and Jounce in $2.6-bn Immuno-Oncology Collaboration Deal

Celgene and Jounce Therapeutics are to join in a global strategic collaboration with the aim of developing and commercialising immuno-oncology treatments. The collaboration will provide Celgene the options to jointly develop and commercialise Jounce’s primary product candidate, JTX-2011, and other innovative immunotherapies targeting B cells, T regulatory cells and tumor-associated macrophages.

Continue Reading

Nanomedicine Combinination Could Improve Outcomes for Pancreatic Cancer Patients

A report has stated that a nanoparticle drug-delivery system that combines two complementary types of anticancer treatment could improve outcomes for patients with pancreatic cancer and other highly treatment-resistant tumours whilst decreasing toxicity. In their report that has received advance online publication in Nature Nanotechnology, a research team based at the Wellman Center for Photomedicine

Continue Reading